Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD. Ross Camidge, Sanjay Popat, Yuichiro Ohe et al.|Lung Cancer|2025Cited by 3
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC.Jonathan W. Goldman, Maximilian J. Hochmair, Weiji Su et al.|Journal of Clinical Oncology|2024Cited by 1
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC.Theresa Bayt, Maximilian J. Hochmair, Jonathan W. Goldman et al.|Journal of Clinical Oncology|2024Cited by 0